BIOCRYST PHARM (BO1 BE) stock market data APIs
€7.8014
0.25(3.2%)
as of March 18, 2026
Try our APIs with
free plan!
BIOCRYST PHARM Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for BO1.BE.
Prev. Close
7.8014
Open
8.0508
High
8.0923
Low
7.7289
52 wk Range
5.536-9.896
Market Cap
1 856 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get BIOCRYST PHARM data using free add-ons & libraries
Get BIOCRYST PHARM Fundamental Data
BIOCRYST PHARM Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-26
- EPS/Forecast: 0.07
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
BIOCRYST PHARM News
New
BioCryst Pharmaceuticals Inc (BCRX) Q4 2025 Earnings Call Highlights: Record Profitability and ...
This article first appeared on GuruFocus. Orlideo Revenue: $601.8 million for full year 2025, up 38% year-over-year, 43% excluding European business. Non-GAAP Total Revenue Growth: Increased 45% year...
BioCryst Reports Full Year 2025 Financial Results and Provides Business Update
BioCryst Pharmaceuticals, Inc. —Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO busin...
Are BioCryst Pharmaceuticals (BCRX) Shares Offering Value After Recent Price Rebound
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. If you are looking at BioCryst Pharmaceuticals and wonder...
BioCryst (BCRX) Is Up 9.5% After Astria Deal And HAE Data Spotlight Has The Bull Case Changed?
Evercore ISI recently reinstated coverage of BioCryst Pharmaceuticals, highlighting the company’s position after its acquisition of Astria Therapeutics and its hereditary angioedema portfolio, inclu...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
